Drug Profile
Fruquintinib - HUTCHMED
Alternative Names: Aiyoute; Elunate; FRUZAQLA; HMPL-013; TAK-113Latest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator Hutchison MediPharma
- Developer BeiGene; Eli Lilly and Company; Genor Biopharma; Hutchison MediPharma; HUTCHMED; Shanghai Junshi Biosciences
- Class Antineoplastics; Benzofurans; Quinazolines; Small molecules
- Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Colorectal cancer
- Preregistration Gastric cancer
- Phase III Non-small cell lung cancer
- Phase II/III Renal cell carcinoma
- Phase II Solid tumours
- Phase I/II Endometrial cancer; Triple negative breast cancer
Most Recent Events
- 28 Feb 2024 HUTCHMED announces intention to complete EMA MAA review for Colorectal cancer (Second-line therapy or greater, Metastatic disease) in mid-2024
- 28 Feb 2024 HUTCHMED announces intention to registration filing to the NMPA for Endometrial cancer (second-line Therapy or greater) in early 2024
- 28 Feb 2024 HUTCHMED expects PMDA to complete NDA review for Colorectal cancer (Second-line therapy or greater, Metastatic disease) in late-2024